HBIO vs SLB · rev $22.7M vs P/E 12, rev $8.97B
Harvard Bioscience Inc (HBIO) versus Schlumberger NV (SLB) — a side-by-side from cached financials, not a winner call.
Harvard Bioscience Inc (HBIO) is a medical instruments & supplies company listed on US.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US.
Latest reported HBIO revenue for 2026-06-30 was $22.7M. Net income was -$2.9M. Revenue was up 9.5% from 2026-03-31 to 2026-06-30. HBIO currently screens at market cap $20.3M.
Latest reported SLB revenue for 2026-06-30 was $8.97B. Net income was $786.0M. Revenue was up 2.9% from 2026-03-31 to 2026-06-30. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
HBIO currently screens at market cap $20.3M. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Not investment advice. Open the HBIO and SLB stock pages for the full models.
Not investment advice.